Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Members of P.A.I.N. (Prescription Addiction Intervention Now) and Truth Pharm staged a rally and die-in last year outside New Yorks Southern District Federal Court in White Plains, where Purdue Pharmaceuticals' bankruptcy hearing was being held. Photo: Erik McGregor/LightRocket via Getty Images

Purdue Pharma, the maker of OxyContin, has agreed to plead guilty to three federal criminal charges and close the company as part of an $8.3 billion settlement, the Justice Department announced Wednesday.

Why it matters: The settlement marks a significant step in the federal government's efforts to hold a major drugmaker responsible for the country's opioid crisis, which has been linked to hundreds of thousands of deaths.

Details: The company agreed to plead guilty to charges including conspiracy to defraud the United States and violating federal anti-kickback laws, DOJ officials said.

  • The company, which filed for bankruptcy in 2019, has also agreed to a $3.544 billion criminal fine and a $2 billion criminal forfeiture.
  • "Further, to resolve its civil liability, Purdue Pharma has agreed to $2.8 billion in damages to the United States," Deputy Attorney General Jeffrey Rosen said in announcing the settlement.
  • "The agreed resolution, if approved, will require that the company must dissolve and no longer exist in its present form, the Sacklers must relinquish all ownership and control of the company (and its successors), and the assets must be transferred to a new public benefit company or PBC owned by a trust for the benefit the American public," Rosen added.
  • "If the bankruptcy court approves this, the department will credit the company for the value conferred through the PBC against the criminal forfeiture amount, except for $225 million that will be paid to the United States on the bankruptcy effective date."
  • The deal doesn't shield any of the company's owners or executives —  including members of the Sackler family — from criminal liability. Members of the family agreed to pay a separate $225 million civil penalty.

Steven Miller, who became chairman of the company’s board in 2018, said in a statement: “Purdue deeply regrets and accepts responsibility for the misconduct detailed by the Department of Justice in the agreed statement of facts."

  • He added, "Purdue today is a very different company. We have made significant changes to our leadership, operations, governance, and oversight."

What they're saying: "Purdue Pharma actively thwarted the United States' efforts to ensure compliance and prevent diversion," Drug Enforcement Administration Assistant Administrator Tim McDermott said at a news conference.

  • "The devastating ripple effect of Purdue's actions left lives lost and others addicted," McDermott said.
  • Rosen added, "Keeping the American people safe is the Department of Justice’s highest priority.  As today’s announcement re-affirms, the department will not relent in our efforts to combat the opioids crisis."

Yes, but: Several states had previously objected to the deal.

  • 25 state attorneys general wrote to Attorney General Bill Barr last week, arguing that the company should not be converted into a public benefit corporation.
  • "[S]elling the business to a private owner may also deliver more upfront money that cities and states can use to abate the opioid epidemic," the officials wrote.
  • "[T]he public should be confident that public officials are seeking to avoid having special ties to an opioid company, conflicts of interest, or mixed motives in an industry that caused a national crisis," the added.
  • The letter said that at least one potential buyer had already come forward.

Go deeper:

Go deeper

Attorney General Barr departs Justice Department

Photo: Michael Reynolds/Pool/AFP via Getty Images

Attorney General Bill Barr sent a parting note to his colleagues on Wednesday to mark the end of his time leading the Department of Justice, stating that it's been a "great honor to serve once again in this role," NBC News reports.

What to watch: Barr will be replaced in an acting capacity by Deputy Attorney General Jeffrey Rosen, who multiple administration officials privately say now has the worst job in Washington.

Erica Pandey, author of @Work
2 hours ago - Economy & Business

What's really going on with the labor market

Source: YCharts

The labor market is showing some signs of improvement: Jobless claims fell to 730,000 — a dramatic drop from 841,000 the previous week. And the latest jobs report showed a pandemic-era low unemployment rate of 6.3%

But, but, but: That's not the full story, experts say.

Felix Salmon, author of Capital
2 hours ago - Economy & Business

Markets see rare convergence milestone

Expand chart
Data: YCharts; Chart: Axios Visuals

A milestone was reached in the markets Thursday: The yield on the 10-year Treasury note rose to match the dividend yield on the S&P 500

Why it matters: The two yields have been inverted since the beginning of last year, which is historically unusual.